USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
OMEROS CORPORATION
Address:
201 Elliott Avenue West
SEATTLE, WA
Phone:
N/A
URL:
N/A
EIN:
911663741
DUNS:
33364923
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,864,599.00 12
SBIR Phase II $2,486,305.00 3

Award List:

INTRA-ARTICULAR DELIVERY OF PEPTIDES AND PROTEINS

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$99,640.00
Agency:
HHS
Principal Investigator:
Paul J. Simpson
Abstract:
Not Available This project will investigate the feasibility of developing a compact, low-power, low-cost light probe to be used for remotely interrogating the fluorescence and reflectance properties of the sea floor and benthic marine organisms at a number of wavelengths. The resultant data would… More

Novel 5-HT treatments for METH post-addiction therapy

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$783,774.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall objective of this research is to identify putative drug treatments in the pre-clinical setting that can rapidly translate into post-withdrawal pharmacotherapy for methamphetamine (METH) addiction. Methamphetamine is an increasingly popular… More

MASP-2 MoAB therapeutics for MI/RP injury

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$127,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall goal is to develop monoclonal antibodies capable of blocking human MASP-2 function as potential therapeutic agents for myocardial ischemia/reperfusion injury. MASP-2 is a plasma serine protease uniquely required for complement activation via the… More

MASP-2 Therapy for Macular Degeneration

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$142,140.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall goal is to develop monoclonal antibody-based compounds capable of blocking human MASP-2 function as potential therapeutic agents for the treatment of age-related macular degeneration (AMD). MASP-2 is a plasm a serine protease uniquely required for… More

Development of Novel Analgesics Targeting a Brain GPCR

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$107,050.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Chronic pain affects over 100 million Americans annually. Opiates are the primary drugs that can treat chronic pain. However, these drugs produce severe unwanted side effects. There is clearly a large, unmet need for dr ugs that can produce analgesia with limited… More

MASP-2: A Potential New Target for Treatment of Rheumatoid Arthritis

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$146,600.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is a severely debilitating disease that affects approximately 0.5-1% of the population. Currently, the most effective treatment for this disease involves the use of one of several anti-TNF ag ents either alone or in combination with… More

A novel therapeutic target for OA that restores IGF-1 responses

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$148,400.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of our research is to develop an effective treatment for osteoarthritis (OA). There is no effective treatment for OA, and the potential market for an OA therapy has been estimated to be 10 billion an nually. To date, efforts to develop a… More

A novel therapeutic target for OA that restores IGF-1 responses

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$334,600.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): This is a revision application under NOT-OD-09-058 entitled NIH Announces the Availability of Recovery Act Funds for Competitive Revision Applications. In this application we propose to expand our research program in order to accelerate the development of a… More

Universal High Throughput GPCR Screening Assay

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$476,876.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): G-protein coupled receptors (GPCR) are a family of cell surface proteins involved in mediating many of the biological actions of neurotransmitters in the brain. It has been estimated that there are approximately 865 GPC Rs in the human genome, making them one of… More

Novel therapy for osteoporosis

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$193,888.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of our research is to develop a novel treatment for osteoporosis that will stimulate bone formation. An estimated 10 million Americans over the age of 50 have osteoporosis, and another 34 million peop le are at high risk of developing this… More

Development of MASP-2 MoAbs for the treatment of diabetic nephropathy

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$198,383.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term objective of this application is to develop a MASP-2 blocking monoclonal antibody as a therapeutic agent to prevent and treat complications of diabetes, namely diabetic nephropathy (DN). DN is the leading cause of end stage renal disease, resulting… More

MASP-2 Therapy for Macular Degeneration

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$660,672.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overall goal is to develop monoclonal antibody (MoAb)-based compounds capable of blocking human MASP-2 function as potential therapeutic agents for the treatment of age-related macular degeneration (AMD). MASP-2 is a plasma serine protease uniquely required… More

Development of NMUR2 Antagonists as Novel Analgesics

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,041,859.00
Agency:
HHS
Principal Investigator:
Neil Cutshall – 206-623-4688
Abstract:
DESCRIPTION (provided by applicant): Pain affects over 100 million Americans annually. Opioids are the primary drugs that can treat pain. However, these drugs produce severe and unwanted side effects, such as respiratory depression, nausea, constipation and tolerance development (Berde et al, 2008);… More

Monoclonal Antibodies for Orphan GPCRs in the CNS

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$697,020.00
Agency:
HHS
Principal Investigator:
Pat Gray – 206-650-6765
Abstract:
DESCRIPTION (provided by applicant): Monoclonal Antibodies for Orphan GPCRs in the CNS GPCRs comprise a large family of structurally related membrane proteins with critical functions in neurobiology. As such, they are key therapeutic targets. However, many members of the vast GPCR family remain… More

MASP-2 Antibodies for Diabetic Neuropathy

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$193,002.00
Agency:
HHS
Principal Investigator:
Thomas A. Dudler – 206-676-0818
Abstract:
DESCRIPTION (provided by applicant): The overall objective of the MASP-2 program is to develop a monoclonal antibody that blocks the function of MASP-2, in order to treat microvascular complications associated with diabetes. The goal of the work proposed in this application is to validate… More